NeuroMab™ Anti-TREM2 Antibody(NRP-0422-P796)

Figure 1 shows the increased agonistic activity of Fc variant anti-TREM2 antibodies. Luciferase activity of Fc variant antibodies co-cultured with BWZ reporter cells and THP-1 cells at a ratio of 1:1 for 6 hours.

Figure 2 shows the increased agonistic activity of Fc variant anti-TREM2 antibodies. Luciferase activity after 6 hours incubation with Fc variant of anti-TREM2 antibody.

Figure 3 shows C3b deposition induced by Fc variant anti-TREM2 antibodies. Fold change in C3b deposition on HEK expressing TREM2 cell lines of AL2p Fc variants relative to human IgG1 isotype control antibody at 10 μg/mL.

Figure 4 shows C3b deposition induced by Fc variant anti-TREM2 antibodies. Fold change in C3b deposition of AL2p affinity matured variants with the listed Fc mutations relative to their parental IgG1 Fc variants.

Figure 5 shows the increase in activity of soluble anti-TREM2 antibody.

Figure 6 shows the increased activity of soluble anti-TREM2 antibodies.

Figure 7 shows sTREM2 secreted by primary human dendritic cells from donor 534 within 48 hours of incubation with anti-TREM2 or control antibody.

Figure 8 shows that after incubation of primary human dendritic cells from donor 534 with anti-TREM2 or control antibody, there was no change in cell number.

Figure 9 shows plasma sTREM2 as a percentage of baseline levels following a single injection of 15 mg/kg of the TREM2 antibodies AL2p-47 huIgG1 , AL2p-47 huIgG1 ASPSEG, AL2p-58 huIgG1 , or control huIgG1.

Figure 10 depicts increased viability (increased cellular ATP) after stimulation of primary human macrophages.

Figure 11 shows Western blot analysis of Dapl2 phosphorylation in WT or TREM2 Bac-Tg mouse peritoneal macrophages treated with AL2p-58 huIgG1 , AL2p-58 huIgG1 PSEG or control huIgG1.